Pfizer’s Crizotinib Eases Past FDA With Targeted Population
FDA is showing for the second time in as many weeks that all things are possible when it comes to clearing targeted oncologics with compelling evidence. The agency cleared Pfizer’s Xalkori (crizotinib) for late-stage non-small cell lung cancer Aug. 26, just under five months from submission and based on early stage evidence.
You may also be interested in...
It now takes 13 drugs in Phase I to yield one marketed drug, compared to 19 in 2007 to 2011, according to new data from KMR Group.
With the launch of Ibrance and a burgeoning immuno-oncology program, Pfizer’s oncology business is on track to generate substantial revenue and investors are starting to take note. Oncology President Liz Barrett and Chief Medical Officer Mace Rothenberg discuss Pfizer’s initiative to become a leader in the field.
Merck plans to enrich its Phase II study for MK-3475 with patients whose tumors express PD-L1; Bristol would take all comers in its Phase I/II trial of nivolumab.